Ip Share Discussion Threads

[p1nkfish] 09/4/2022 16:49

Would vote to take IP Group private if that was a resolution at next AGM.
At least save the listing costs.
I can't see a good reason to be listed when they already have so much cash.
Not like they need to raise any anytime soon???

The lack of UK Tech listings has been a complaint in the recent past but when we do have the likes of IP Group it's hardly valued at all at its real worth.

[bamboo2] 09/4/2022 13:20

Header partially updated. Please post any info you would like added to it.
I have slightly lost touch of current rolling cash and NAV, so any suggestions welcome.
=======================

p1nk, Re, "This is a very good lesson on the role sentiment plays in determining a market price."

I think you are right to say that.
The market doesn't believe the news from FLF has any financial worth and has rejected it. Reading The Telegraph and other news articles and comments about the FLF news, it is slightly ironic that one of the biggest moans in the comment section is that it has Tencent as a backer.

Maybe the reason so much of our tech finds its way abroad, is that there is simply no real support in the UK market for companies like IPGroup.

[bamboo2] 09/4/2022 11:36

Kynos Therapeutics Ltd - Emerges from stealth with £9m financing and Phase 1-ready KMO Inhibitor
07 Apr 2022

Spin-out from the University of Edinburgh commercialising a decade of drug discovery research on kynurenine 3-monooxygenase (KMO), a pivotal enzyme in the kynurenine pathway of tryptophan metabolism
Kynos programmes are focused on three key areas: in critical illness post-surgery; in conditions driven by inflammation; and in cancers where inflammation is preventing the immune system from fighting back
£9m financing made up of £6.5m equity financing led by Epidarex Capital, together with IP Group and Scottish Enterprise, alongside £2.5m Innovate UK grant funding for a Phase 1 clinical trial of lead KMO inhibitor
Innovative pipeline of first-in-class KMO inhibitors exclusively licensed from the University of Edinburgh after a co-development programme with GSK
Company led by industry-experienced team with world-leading knowledge in KMO biology, Professor Damian Mole, CEO and Professor Scott Webster, CSO
EDINBURGH, Scotland, April 7, 2022 /PRNewswire/ -- Kynos Therapeutics Ltd (Kynos or the Company), an immune-metabolic company with world-leading expertise in the kynurenine pathway and kynurenine 3-monooxygenase (KMO) biology, today emerges from stealth mode with £9 million to finance its lead KMO inhibitor (KMOi) programme through Phase 1 clinical trials and to progress its innovative pipeline of first-in-class KMOi across key indications in inflammation, immunity and metabolism.

Kynos is a spin-out from the University of Edinburgh (UoE), based on over a decade of research into KMO biology and its inhibitors. Its technology and KMOis were co-developed during a multi-year collaborative programme between the UoE founders and GSK. The collaboration concluded in 2019 and data packages and all rights and intellectual property were transferred to the UoE. GSK is eligible for a royalty should a medicine be registered.

The £6.5m Initial Venture Financing Round Was Led By Epidarex Capital, Joined By Ip Group And Scottish Enterprise. Kynos Has Also Been Awarded £2.5m Through An Innovate Uk Grant To Fund A First-time In Human Phase 1 Clinical Trial Of Its Lead Kmoi, Kns366. Kynos Has A Completed Ind-enabling Package And Is Preparing To Start A Single Ascending Dose Study With Biomarker Analysis.

KMO plays a major role in the control of inflammation and metabolism, contributing to the regulation of the immune system. It is a mitochondrial enzyme that converts kynurenine into biologically active 3HK that damages cells. Blocking KMO reduces 3HK, protecting against tissue damage.

Kynos's pipeline is focused on three key areas: in critical illness post-surgery; in conditions driven by inflammation; and in cancers where inflammation is preventing the immune system from fighting back. This financing will be used to build out its core team and to fund preclinical indication expansion studies as well as to initiate development of oral formulations of KMO inhibitors. These activities will run in parallel to the Innovate UK-funded Phase 1 clinical trial in humans.

Kynos's core founding team are leading experts in KMO biology and medicinal chemistry with clinical, translational and drug discovery experience: CEO Damian J Mole (Professor of Surgery and MRC Senior Clinical Fellow, the University of Edinburgh Centre for Inflammation Research; and CSO Scott Webster (Professor of Medicines Discovery, Centre for Cardiovascular Science, University of Edinburgh). The industry engagement and launch of the spin-out company have been supported by Edinburgh Innovations, the University of Edinburgh's commercialisation service.

Professor Damian Mole, CEO of Kynos Therapeutics, said: "Our goal is to improve health and make a positive impact for patients, by developing our programme in the therapeutic area of inflammation and immunometabolism. We are very excited by the potential of our first-in-class KMO inhibitors and we are ready to enter the clinic with our lead asset.

"Our programmes are based on extensive industry collaborative research with a robust science base supported by multiple high impact publications. There are no approved or marketed medicines for our gateway indication, for which there is a significant unmet need."

Following the Financing Dr Elizabeth Roper, Partner at Epidarex Capital, and Dr Tassos Konstantinou, Investment Manager, Life Sciences at IP Group plc, have joined Kynos's board of directors.

Dr Elizabeth Roper, Partner at Epidarex Capital and Kynos Investor Director, said: "Kynos has a first-in-class set of KMO inhibitors that we believe have potential in multiple therapeutic areas. We look forward to working closely with the team and the syndicate to progress these assets into the clinic and to realise the potential of Kynos's world-class science."

Dr Sam Williams, Managing Partner of Life Sciences at IP Group plc, said: "KMO is rapidly becoming a target of great interest in drug discovery. IP Group is excited to support Kynos as it seeks to become a leading player in the KMO field and develop inhibitors with the potential to transform patients' lives across multiple indications."

Kerry Sharp, Director of Growth Investments at Scottish Enterprise said: "Scotland is globally renowned for its strengths in life sciences because of our innovative companies, incredible talent and world-class universities. Supporting companies in this sector, such as Kynos Therapeutics, to progress its ground-breaking medical research is a priority for Scottish Enterprise. Kynos is developing an innovative portfolio of first-in-class medicines and this funding will help deliver therapies for patients impacted by inflammatory conditions."

About Kynos Therapeutics – www.kynostx.com

Kynos Therapeutics is developing an innovative portfolio of first-in-class medicines where there is an unmet medical need for new therapies. It is a spin-out from the University of Edinburgh commercialising a decade of drug discovery research on kynurenine 3-monooxygenase (KMO), a pivotal enzyme in the kynurenine pathway of tryptophan metabolism. Its innovative pipeline of first-in-class KMO inhibitors across key indications in inflammation, immunity and metabolism, was originally co-developed through a collaboration between GSK and the University of Edinburgh and is now exclusively licensed to Kynos.

Based in Edinburgh, UK, the company is financed by equity investment led by Epidarex Capital joined by IP Group plc and Scottish Enterprise, as well as a grant from Innovate UK.

[p1nkfish] 08/4/2022 08:16

This is a very good lesson on the role sentiment plays in determining a market price.

[palisz] 08/4/2022 07:49

Oh dear! No one else got the heart to tell poor Pierre....
The annual results came out on the 16th March...followed by a presentation.
Perhaps you should go on the website and request news notifications.
Then watch the replay...most of your questions will be answered.
FYI.. Results were as expected, Presentation focused on progress with a variety of exciting companies...just market currently doesn't care. Growth companies still concerned by rising interest rates. Your Welcome.

[p1nkfish] 05/4/2022 20:56

Robert Trezona is on YouTube wrt FLF and the IP Group approach and involvement from day 1. A short and sweet video.

[pierre oreilly] 05/4/2022 10:07

Should be annual results soon, let's see what they say there.

The ONLY thing they have to do is become more shareholder friendly. They have oodles of cash, investments left in nano, about to be highly profitable in flf (and well done to them under almost impossible odds) - everything except a desire to share the massive spoils with shareholders. The intrisnic value, ime, is about 2x the share price, and that could be corrected easily imv.

100% divi rise please, for a starter, as a signal of better returns to shareholders.

[p1nkfish] 05/4/2022 09:14

Imagine helping achieve the below by owning stock in just one company:

1) Address C02 issues
2) Help banish fuel poverty
3) Help UK gain back some if not all of its dynamism
++++++++

That is what FLF might achieve and ordinary people have a stake via a holding in IP Group.
That's why I continue to hold this otherwise disappointing share.

There is then the impact of the likes of ONT on future health and well-being.

IP don't make enough noise.

[bamboo2] 05/4/2022 08:14

Let me know if you want the RNS above edited further!

Market says 'Meh'.

I guess this will enable the co to bring in additional partners/investors.
IPGroup normally use these ops to take something off the table.

[palisz] 05/4/2022 07:05

First Light Fusion Ltd has confirmed that it has achieved fusion which has been independently validated by the UK Atomic Energy Authority (UKAEA). I think this is pretty big!

[p1nkfish] 01/4/2022 07:39

ONT get their £50M.

"........which included agreement as to the contract being brought to an end and includes a payment of £50 million in full of amounts due to ONT under the contract.

ONT expects the payment to be treated as non-recurring COVID-19 testing revenue during the fiscal year ended 31 December 2022. Therefore, ONT's prior guidance for Life Science Research Tools revenue in 2022 remains unchanged."

[p1nkfish] 31/3/2022 20:28

Would be useful if we had some sustainable fertiliser investments in the portfolio.

[wba1] 31/3/2022 20:15

Interesting story in the Standard today about the first completely gapless sequencing of the human genome, and referencing sequencing machines made by ONT (and Pacific Bio). Good publicity.

[apple53] 31/3/2022 12:16

Did anyone ask in the meeting about restarting share repurchases?
Seems like a no-brainer still.

[wba1] 24/3/2022 10:17

I have just read Stuart Ritchie's exposure of the crisis in science research (Science Fictions) caused by a system which incentivises sloppy use of research methodology, statistics and peer review. It contains some interesting points relevant to IP portfolio companies.
* it observes that a large percentage of research involving the use of cell lines (over 50% of papers from China and 30%+ elsewhere) is rendered useless due to cell line contamination. This implies that any lab using cell lines requires sequencing technology and should be an obvious target market for ONT. Perhaps ONT should shout about the problem and encourage journals to decline papers which cannot confirm the purity of their cell lines.
* it has a substantial discussion on the hype around microbiome research and exploitation by the nutrition sector. In the light of the recent fundraising from Microbiotica this may be one to treat with caution.
For those who do not know, Ritchie is a very well regarded scientist and academic at Kings, London. He is more in the style of Ben Goldacre (the Oxford academic and science journalist who has exposed numerous frauds). So when he speaks it is worth listening.

[kooba] 22/3/2022 07:31

https://www.telegraph.co.uk/investing/shares/questor-investment-company-back-trading-big-discount-hold/

[kooba] 20/3/2022 09:01

https://twitter.com/thestmagazine/status/1505454581089714178?s=21Big piece on FLF in the Sunday Times magazine.

[bamboo2] 17/3/2022 08:49

Investor Meet have the FY 2021 presentation on Youtube.

I am not sure if this is a recording of yesterday mornings presentation, or a second recording later in the day.

I guess from the intro, it is a separate recording.

Greg Smith sounds a lot better than in previous presentations, and the whole webinar process seemed much smoother with zero gremlins!

[bamboo2] 16/3/2022 23:03

Hysata, an Australian hydrogen technology company, has developed an ultra-high efficiency electrolyser, a major breakthrough in the industry’s attempt to reach the commercialisation milestone of producing a kilogram of hydrogen for under $2...

...“An existing electrolyser is about 75 per cent efficient, which means 25 per cent of the energy put in is wasted. We are at 95 per cent, so a 20 per cent increase over the incumbents. This is a game changer.

[p1nkfish] 16/3/2022 21:46

Critically important to a future prosperous UK. IP Group portfolio has a part to play.

[p1nkfish] 16/3/2022 21:43

No arguing there are some potential champions in the portfolio that could have a massively positive impact on many millions of people and the planet. How best to make that show up in the share price

[bamboo2] 16/3/2022 12:10

Results well received, with a possible breakaway gap up this morning.

Update on Istesso was interesting. The expanded Phase 2a Trial with 200 patients will discover optimum treatment dose. The last trial [completed 2019] was continued for 12 weeks, but this one could be longer term.

Many of the constituents have experienced C-19 based delays, hopefully Istesso and Artois will be able to start their latest trials imminently.